Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib Maintenance in Newly Diagnosed Mantle Cell Lymphoma
NCT03616782Phase 2Recruiting
- Start
- Dec 2018
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ixazomib in mantle cell lymphoma (MCL). Primary endpoint: Progression-Free Survival at 2 years. Started Dec 2018; status: recruiting.
02
Drugs
ixazomib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03616782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03616782.